FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

 FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

Shots:

  • The P-III LELANTOS-2 study will assess Pamrevlumab + systemic corticosteroids vs PBO + systemic corticosteroids in ~70 patients aged 6-12yrs. in a ratio (1:1) with ambulatory DMD for up to 52wks.
  • The focus of the study is to assess the effect of Pamrevlumab on muscle function in patients with DMD with 1EPs as an ambulatory function assessment, measured by NSAA. Additionally, 2EPs will be assessed in the study
  • Patients who complete the 52wks. study will be eligible for rollover into an OLE study with Pamrevlumab and systemic corticosteroids. Pamrevlumab is a first-in-class antibody that inhibits the activity of CTGF

Click here ­to­ read full press release/ article | Ref: Fibrogen | Image: Fibrogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post